SOLVD
1991
Studies of Left Ventricular Dysfunction — Treatment Trial
In 2,569 patients with symptomatic heart failure and EF ≤ 0.35, enalapril reduced all-cause mortality compared with placebo.
Result
- Absolute difference
- 4.5 points
- NNT
- 23
relative risk reduction1695% CI 5-26 · P = 0.0036
Absolute difference and NNT are derived from the event rates.
Also reported: Over mean 41.4 months; HF hospitalisations also reduced.
- Subtopic
- ACE inhibitor
- Design
- Double-blind placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Source
- SOLVD Investigators (Yusuf S, et al). N Engl J Med. 1991;325(5):293-302.doi 10.1056/NEJM199108013250501
Discussion & critique
Predates modern background therapy (beta-blockers, MRAs, devices), so absolute benefit differs today. Foundational trial establishing ACE inhibitors as cornerstone therapy for symptomatic HFrEF.